Literature DB >> 21713599

Intravenous diazepam, midazolam and lorazepam in acute seizure control.

Geeta Gathwala1, Mayank Goel, Jagjit Singh, Kundan Mittal.   

Abstract

OBJECTIVE: To evaluate the safety and efficacy of three benzodiazepine drugs: Lorazepam, Midazolam and Diazepam, when given parenterally in the control of acute seizure.
METHODS: One hundred and twenty children of either sex in the age group 6 month to 14 years brought convulsing to the pediatric emergency services, were enrolled in the study. These were randomised to three equal groups of 40 patients each; Group A-received diazepam, Group B-received midazolam, Group C-received lorazepam. End of seizure episode (clinically) was defined as cessation of visible epileptic phenomenon or return of purposeful response to external stimuli within 15 min of drug administration. A stopwatch was used to measure various time intervals accurately. The patient's vitals were monitored and recorded in a predesigned performa. The primary outcome was the time to seizure cessation and secondary outcome was the side effects of the drugs. Data obtained was analysed statistically using student's t-test and chi-square test.
RESULTS: Mean duration to clinical seizure cessation was comparable among the three groups. For diazepam group it was 84.94 ± 38.56 s, for midazolam group it was 92.69 ± 25.97 s, for lorazepam group it was 91.12 ± 23.58 s. Number of patients with any abnormality in seizure cessation were significantly higher in diazepam group [11/40 (27.5%)] when compared to the midazolam [4/40 (10%)] and lorazepam group [2/40 (5%)]. Number of patients requiring 2nd dose to control seizures was significantly higher [4/40 (10%)] in diazepam group when compared to lorazepam group [0/40 (0%)] but diazepam and midazolam and midazolam and lorazepam were comparable in this aspect.All the three drugs were comparable in terms of side effects except excessive somnolence which was significantly higher in diazepam group.
CONCLUSIONS: All the three groups were comparable in terms of time to clinical seizure cessation, seizure recurrence and uncontrolled seizures after drug administration. However, number of patients requiring second dose to control seizures were significantly higher in diazepam group when compared to lorazepam group. Excessive somnolence and sedation occurred more frequently with diazepam.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21713599     DOI: 10.1007/s12098-011-0505-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  18 in total

Review 1.  Status epilepticus.

Authors:  U A Hanhan; M R Fiallos; J P Orlowski
Journal:  Pediatr Clin North Am       Date:  2001-06       Impact factor: 3.278

2.  Midazolam as a first-line agent for status epilepticus in children.

Authors:  H Yoshikawa; S Yamazaki; T Abe; Y Oda
Journal:  Brain Dev       Date:  2000-06       Impact factor: 1.961

Review 3.  Status epilepticus: current concepts.

Authors:  A Haafiz; N Kissoon
Journal:  Pediatr Emerg Care       Date:  1999-04       Impact factor: 1.454

Review 4.  Seizure management in pediatric patients for the nineties.

Authors:  S M Wolf; J G Ochoa; E E Conway
Journal:  Pediatr Ann       Date:  1998-10       Impact factor: 1.132

5.  Intramuscular midazolam vs intravenous diazepam for acute seizures.

Authors:  Ira Shah; C T Deshmukh
Journal:  Indian J Pediatr       Date:  2005-08       Impact factor: 1.967

6.  Prognosis in convulsive status epilepticus.

Authors:  G G Celesia
Journal:  Adv Neurol       Date:  1983

7.  A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus.

Authors:  H R Cock; A H V Schapira
Journal:  QJM       Date:  2002-04

8.  Double-blind study of lorazepam and diazepam in status epilepticus.

Authors:  I E Leppik; A T Derivan; R W Homan; J Walker; R E Ramsay; B Patrick
Journal:  JAMA       Date:  1983-03-18       Impact factor: 56.272

9.  Convulsive status epilepticus in infants and children. A study of 239 cases.

Authors:  J Aicardi; J J Chevrie
Journal:  Epilepsia       Date:  1970-06       Impact factor: 5.864

Review 10.  Epilepsy in children.

Authors:  Renzo Guerrini
Journal:  Lancet       Date:  2006-02-11       Impact factor: 79.321

View more
  6 in total

1.  Benzodiazepines for acute management of seizures.

Authors:  Satinder Aneja
Journal:  Indian J Pediatr       Date:  2012-02-16       Impact factor: 1.967

Review 2.  Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.

Authors:  Amy McTague; Timothy Martland; Richard Appleton
Journal:  Cochrane Database Syst Rev       Date:  2018-01-10

Review 3.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

4.  Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus.

Authors:  Lawrence C Ku; Christoph P Hornik; Ryan J Beechinor; James M Chamberlain; Jeffrey T Guptill; Barrie Harper; Edmund V Capparelli; Karen Martz; Ravinder Anand; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-09-28

Review 5.  Comparison of diazepam and lorazepam for the emergency treatment of adult status epilepticus: a systemic review and meta-analysis.

Authors:  Hitoshi Kobata; Toru Hifumi; Eisei Hoshiyama; Kazuma Yamakawa; Kentaro Nakamura; Mitsuhito Soh; Yutaka Kondo; Shoji Yokobori
Journal:  Acute Med Surg       Date:  2020-11-04

Review 6.  Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Adam Strzelczyk; Laurent M Willems; Ricardo Kienitz; Lara Kay; Isabelle Beuchat; Sarah Gelhard; Sophie von Brauchitsch; Catrin Mann; Alexandra Lucaciu; Jan-Hendrik Schäfer; Kai Siebenbrodt; Johann-Philipp Zöllner; Susanne Schubert-Bast; Felix Rosenow
Journal:  CNS Drugs       Date:  2022-08-16       Impact factor: 6.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.